Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 9 de 9
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Artículo en Inglés | MEDLINE | ID: mdl-38601272

RESUMEN

An 82-year-old man had been treated for lung adenocarcinoma and hepatocellular carcinoma (HCC). Contrast-enhanced computed tomography examination showed swelling of the left adrenal gland, suggesting metastasis of lung adenocarcinoma, HCC, or primary adrenal tumor. Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) was performed for the pathological diagnosis, and adrenal metastasis of HCC was diagnosed. No notable complications due to EUS-FNA were found. There have been reports of adrenal metastasis due to various cancers, but there are few reports that can confirm the diagnosis of adrenal metastasis of HCC using EUS-FNA. Adrenal metastasis of HCC is not a rare condition, but it may be difficult to diagnose in the case of multiple cancer complications. We experienced a case in which EUS-FNA was useful for the diagnosis of adrenal metastasis of HCC.

2.
J UOEH ; 45(2): 123-127, 2023.
Artículo en Inglés | MEDLINE | ID: mdl-37258244

RESUMEN

A 57-year-old man visited our hospital for acute cholangitis due to common bile duct (CBD) stones in March 2021. Biliary stenting was performed without any complications. The cholangitis improved rapidly. He was re-hospitalized to treat the CBD stones in May 2021. Although endoscopic retrograde cholangiopancreatography was performed, endoscopy caused a perforation of the duodenal bulb. We successfully performed endoscopic closure of the duodenal defect using an over-the-scope clip (OTSC®). Considering that mild CBD dilatation of 10 mm can carry an increased risk of stenosis after surgery, we decided to avoid surgery and perform a follow-up endoscopic treatment. He was re-hospitalized in July 2021. The endoscopy revealed OTSC® in the anterior wall of the duodenal bulb and complete healing of the perforation. We carefully advanced the scope to the second portion of the duodenum while avoiding OTSC®, and the ampulla of Vater was identified. We were then able to remove the stones without any complications. OTSC® was effective in closing a duodenal perforation and enabled us to carry out the retreatment safely and successfully.


Asunto(s)
Colangiopancreatografia Retrógrada Endoscópica , Colangitis , Masculino , Humanos , Persona de Mediana Edad , Colangiopancreatografia Retrógrada Endoscópica/efectos adversos , Endoscopía Gastrointestinal , Colangitis/etiología , Conducto Colédoco , Resultado del Tratamiento , Estudios Retrospectivos
3.
J UOEH ; 44(4): 353-358, 2022.
Artículo en Inglés | MEDLINE | ID: mdl-36464309

RESUMEN

An 89-year-old man with polycystic liver disease (PCLD) received uncovered self-expandable metallic stent (SEMS) placement above the papilla for malignant biliary obstruction caused by cholangiocarcinoma. He developed cholangitis ten months later due to SEMS occlusion caused by tumor ingrowth, and 2 plastic biliary stents were placed inside the SEMS across the papilla. Fever and right costal pain appeared two weeks after reintervention. Suspecting hepatic cyst infection based on imaging studies, percutaneous transhepatic cyst drainage was performed. Increased inflammatory cells and the presence of pathogens in the cyst fluid led to a definitive diagnosis of hepatic cyst infection. Following drainage, the hepatic cyst shrank with resolution of the symptoms. SEMS occlusive-related cholangitis or retrograde infection due to duodenal-biliary reflux after reintervention was considered as the cause of the hepatic cyst infection. Careful clinical and imaging evaluation should be performed in patients with PCLD undergone biliary stenting, because cyst infection may occur following stent occlusion or subsequent biliary reintervention.


Asunto(s)
Colangitis , Colestasis , Quistes , Hepatopatías , Anciano de 80 o más Años , Humanos , Masculino , Colangitis/etiología , Colestasis/complicaciones , Quistes/complicaciones , Quistes/diagnóstico por imagen , Quistes/microbiología , Hepatopatías/diagnóstico por imagen , Hepatopatías/etiología , Hepatopatías/microbiología
4.
J UOEH ; 44(3): 287-292, 2022.
Artículo en Inglés | MEDLINE | ID: mdl-36089347

RESUMEN

Pancreatic neuroendocrine carcinoma (NEC) as classified in the World Health Organization (WHO) 2010 was reclassified in the WHO 2017 as either neuroendocrine tumor (NET) G3 or NEC. An accurate diagnosis based on the WHO 2017 classification is important in order treating this disease appropriately. We report a case diagnosed as NET G3 that responded remarkably well to treatment with streptozocin. The patient would likely not have received the streptozocin treatment if she had been diagnosed with NEC. The WHO 2017 classification is reasonable for the treatment of advanced pancreatic neuroendocrine neoplasms.


Asunto(s)
Tumores Neuroendocrinos , Neoplasias Pancreáticas , Femenino , Humanos , Clasificación del Tumor , Tumores Neuroendocrinos/tratamiento farmacológico , Tumores Neuroendocrinos/patología , Neoplasias Pancreáticas/tratamiento farmacológico , Neoplasias Pancreáticas/patología , Estreptozocina/uso terapéutico
5.
Intern Med ; 61(14): 2155-2160, 2022.
Artículo en Inglés | MEDLINE | ID: mdl-35850987

RESUMEN

A 70-year-old man was referred to our department for the treatment of early gastric cancer. Contrast-enhanced computed tomography (CT) incidentally showed diffuse enlargement of the pancreas with a capsule-like rim, and blood tests showed elevated serum IgG4 levels, leading to a diagnosis of autoimmune pancreatitis (AIP). Endoscopic treatment for gastric cancer was performed, and pathological findings showed adenocarcinoma with abundant IgG4-positive plasma cell infiltration. Thereafter, the serum IgG4 levels normalized, and the findings of AIP disappeared on CT without steroid treatment. These findings suggest that the gastric cancer activated an IgG4-related immune response, resulting in the development of AIP.


Asunto(s)
Enfermedades Autoinmunes , Pancreatitis Autoinmune , Enfermedad Relacionada con Inmunoglobulina G4 , Pancreatitis , Síndromes Paraneoplásicos , Neoplasias Gástricas , Anciano , Enfermedades Autoinmunes/complicaciones , Enfermedades Autoinmunes/diagnóstico , Humanos , Inmunoglobulina G , Enfermedad Relacionada con Inmunoglobulina G4/complicaciones , Enfermedad Relacionada con Inmunoglobulina G4/diagnóstico , Masculino , Pancreatitis/complicaciones , Pancreatitis/diagnóstico , Síndromes Paraneoplásicos/diagnóstico , Síndromes Paraneoplásicos/etiología , Neoplasias Gástricas/complicaciones , Neoplasias Gástricas/diagnóstico
6.
Anticancer Res ; 40(9): 5271-5276, 2020 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-32878816

RESUMEN

BACKGROUND/AIM: Hepatic encephalopathy is an adverse event resulting from lenvatinib use in patients with hepatocellular carcinoma (HCC). We analyzed the influence of lenvatinib on portal venous flow velocity (PVV) and serum ammonia concentration. PATIENTS AND METHODS: Eleven patients with unresectable HCC were enrolled, including three with modified albumin-bilirubin (mALBI) grade 1, three with grade 2a, and five with grade 2b. PVV was measured by Doppler ultrasound sonography before and on day 2 of administration. RESULTS: Out of 11 patients, one developed hepatic encephalopathy. PVV was reduced in 10 patients, and the change from baseline was significantly correlated with lenvatinib dosage. The increase in serum ammonia concentration was affected by lenvatinib dose and baseline hepatic function as a threshold between mALBI grade 2a and 2b statistically. There was no correlation between changes in PVV and serum ammonia concentration. CONCLUSION: Lenvatinib might directly disturb hepatocyte metabolism to result in increased serum ammonia concentration.


Asunto(s)
Antineoplásicos/efectos adversos , Carcinoma Hepatocelular/complicaciones , Carcinoma Hepatocelular/tratamiento farmacológico , Hiperamonemia/etiología , Neoplasias Hepáticas/complicaciones , Neoplasias Hepáticas/tratamiento farmacológico , Compuestos de Fenilurea/efectos adversos , Inhibidores de Proteínas Quinasas/efectos adversos , Quinolinas/efectos adversos , Anciano , Anciano de 80 o más Años , Antineoplásicos/administración & dosificación , Antineoplásicos/uso terapéutico , Bilirrubina/sangre , Carcinoma Hepatocelular/diagnóstico , Susceptibilidad a Enfermedades , Femenino , Encefalopatía Hepática/diagnóstico , Encefalopatía Hepática/etiología , Humanos , Hiperamonemia/diagnóstico , Pruebas de Función Hepática , Neoplasias Hepáticas/diagnóstico , Masculino , Persona de Mediana Edad , Clasificación del Tumor , Estadificación de Neoplasias , Compuestos de Fenilurea/administración & dosificación , Compuestos de Fenilurea/uso terapéutico , Vena Porta/fisiopatología , Inhibidores de Proteínas Quinasas/administración & dosificación , Inhibidores de Proteínas Quinasas/uso terapéutico , Quinolinas/administración & dosificación , Quinolinas/uso terapéutico , Factores de Riesgo
7.
Med Mol Morphol ; 53(1): 50-55, 2020 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-31161407

RESUMEN

Idiopathic copper toxicosis (ICT) is characterized by marked copper deposition, Mallory-Denk body (MDB) formation and severe hepatic injury. Although the characteristics are apparently different from Wilson disease, large amounts of copper accumulate in the liver of the patients. We extensively treated a patient with ICT to reduce the body copper, however, the patient needed liver transplantation. Previous liver biopsy revealed high copper content. But extirpated liver contained an extremely small amount of copper, although MDBs and severe inflammation remained. These phenomena suggest abnormal copper metabolism is not the principle cause of ICT but some other abnormality must exist.


Asunto(s)
Carcinoma Hepatocelular/patología , Enfermedad Hepática Inducida por Sustancias y Drogas/patología , Cobre/metabolismo , Cobre/toxicidad , Degeneración Hepatolenticular/patología , Cirrosis Hepática/patología , Neoplasias Hepáticas/patología , Trasplante de Hígado , Errores Innatos del Metabolismo de los Metales/patología , Carcinoma Hepatocelular/tratamiento farmacológico , Carcinoma Hepatocelular/metabolismo , Carcinoma Hepatocelular/cirugía , Ceruloplasmina/metabolismo , Quelantes/uso terapéutico , Enfermedad Hepática Inducida por Sustancias y Drogas/tratamiento farmacológico , Enfermedad Hepática Inducida por Sustancias y Drogas/metabolismo , Enfermedad Hepática Inducida por Sustancias y Drogas/cirugía , Femenino , Hepatocitos/metabolismo , Hepatocitos/patología , Degeneración Hepatolenticular/tratamiento farmacológico , Degeneración Hepatolenticular/metabolismo , Degeneración Hepatolenticular/cirugía , Humanos , Hígado/metabolismo , Hígado/patología , Hígado/cirugía , Cirrosis Hepática/tratamiento farmacológico , Cirrosis Hepática/metabolismo , Cirrosis Hepática/cirugía , Neoplasias Hepáticas/tratamiento farmacológico , Neoplasias Hepáticas/metabolismo , Neoplasias Hepáticas/cirugía , Errores Innatos del Metabolismo de los Metales/tratamiento farmacológico , Errores Innatos del Metabolismo de los Metales/metabolismo , Errores Innatos del Metabolismo de los Metales/cirugía , Trientina/uso terapéutico , Adulto Joven
8.
Neuroradiol J ; 32(6): 452-457, 2019 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-31478451

RESUMEN

AIM: The most appropriate imaging protocol for three-dimensional rotational venography (3D RV) has not been established. The aim of this study was to optimise the protocol for 3D RV with low-dose contrast media using time-density curve analysis. METHODS: Twenty-five consecutive patients with brain tumours who received preoperative assessment with 3D RV were retrospectively collected and included in this study. To optimise the imaging delay time of 3D RV with low-dose contrast media, time-density curve analysis was performed on two-dimensional conventional angiography. The image quality for depicting cortical veins and venous sinuses was compared to that of magnetic resonance (MR) venography in five cases. RESULTS: A total of 27 3D RVs were performed in 25 patients. The time-density curves of cortical veins were different from those of cerebral arteries or sinuses. The mean time to peak of cortical veins was significantly longer than the time to peak of cerebral arteries (2.47 ± 0.35 seconds vs. 6.44 ± 1.14 seconds; p < 0.0001) and shorter than the time to peak of venous sinuses (6.44 ± 1.14 seconds vs. 8.18 ± 1.12 seconds; p < 0.0001). The optimal imaging delay time could be determined as the phases in which cortical arterial opacities disappeared and cortical veins started to appear. The mean dose of injected contrast media was 5.3 mL. The image quality of cortical veins in 3D RV was superior to that in MR venography in all cases. CONCLUSIONS: Three-dimensional RV with low-dose contrast media was useful for the preoperative assessment of cortical veins in patients with brain tumours.


Asunto(s)
Neoplasias Encefálicas/cirugía , Angiografía Cerebral/métodos , Venas Cerebrales/diagnóstico por imagen , Senos Craneales/diagnóstico por imagen , Imagenología Tridimensional/métodos , Flebografía/métodos , Adulto , Anciano , Medios de Contraste/administración & dosificación , Femenino , Humanos , Angiografía por Resonancia Magnética , Masculino , Persona de Mediana Edad , Cuidados Preoperatorios , Adulto Joven
9.
Intern Med ; 56(18): 2471-2474, 2017 Sep 15.
Artículo en Inglés | MEDLINE | ID: mdl-28824076

RESUMEN

A 78-year-old man presented with cutaneous blisters of the limbs and abdominal distension. He had been treated for various diseases, including liver cirrhosis. He had begun receiving sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, for diabetes mellitus three years before the hospitalization. A skin biopsy demonstrated bullous pemphigoid. Ultrasonography (US) revealed multiple liver tumors, although he had been receiving regular US studies. We stopped sitagliptin and started insulin and corticosteroids. However, his renal dysfunction progressed, and he died 14 days after the hospitalization. We should therefore be careful of various complications, including bullous pemphigoid and progression of tumors, when using DPP-4 inhibitors.


Asunto(s)
Carcinoma Hepatocelular/patología , Inhibidores de la Dipeptidil-Peptidasa IV/efectos adversos , Cirrosis Hepática/patología , Neoplasias Hepáticas/patología , Penfigoide Ampolloso/inducido químicamente , Fosfato de Sitagliptina/efectos adversos , Anciano , Diabetes Mellitus/tratamiento farmacológico , Inhibidores de la Dipeptidil-Peptidasa IV/uso terapéutico , Humanos , Hipoglucemiantes/efectos adversos , Masculino , Fosfato de Sitagliptina/uso terapéutico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...